Botulinum neurotoxin has been shown to be effective when used in the management of lower urinary tract dysfunction, prostatic disorders and more recently vaginismus in women suffering with pelvic floor muscle tension. Here we provide an overview of the use and efficacy of botulinum toxin in these conditions.
ShuklaHD, SharmaSK. Clostridium botulinum: a bug with beauty and weapon.Crit Rev Microbiol2005; 31: 11–8.
2.
SloopRR, ColeBA, EscutinRO. Human response to botulinum toxin injection: type B compared with type A.Neurology1997; 49: 189–94.
3.
NaumannM, AlbaneseA, HeinenF, MolenaersG, ReijaM. Safety and efficacy of botulinum toxin type A following long-term use.Eur J Neurol2006; 13(suppl. 4): 35–40.
DresslerD. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.Movement Disord2004; 19(suppl. 8): S92–100.
6.
ApostolidisA, DasguptaP, FowlerCJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detruser overactivity.Eur Urol2006; 49: 644–50.
7.
De SezeM, PetitH, GallienP. Botulinum A toxin and detruser sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease.Eur Urol2002; 42: 56–62.
8.
GiannantoniA, Di StasiSM, StephenRL, BiniV, CostantiniE, PorenaM. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detruser overactivity: a prospective randomized study.J Urol2004; 172: 240–3.
9.
EhrenI, VolzD, FarrellyE. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detruser overactivity: a randomized, placebo-controlled double-blind study.Scand J Urol Nephrol2007; 41: 335–40.
10.
SchurchB, DenysP, KozmaCM, ReesePR, SlatonT, BarronRL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.Eur Urol2007; 52: 850–8.
11.
NeelKF, SolimanS, SalemM, SeidaM, Al-HazmiH, KhatabA. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder.J Urol2007; 178: 2593–8.
12.
GheiM, MarajBH, MillerR. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled crossover trial.J Urol2005; 174: 1873–7.
13.
PatelAK, PattersonJM, ChappleCR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results.Eur Urol2006; 50: 684–709.
14.
SahaiA, KhanMS, DasguptaP. Efficacy of botulinum toxin-A for treating idiopathic detruser overactivity: results from a single centre, randomized, double-blind, placebo-controlled trial.J Urol2007; 177: 2231–6.
15.
KuoHC. Recovery of detrusor functions after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction.Urology2007; 69: 57–61.
16.
KuoHC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity.Urology2006; 68: 993–7.
17.
KuoHC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity.J Urol2007; 178: 1359–63.
18.
De LaetK, WyndaeleJJ. Adverse events after Botulinum A toxin injection for neurogenic voiding disorders.Spinal Cord2005; 43: 397–9.
19.
GheiM, MarajBH, NathanS, Malone-LeeJ, MillerR. Autonomic side effects of Botulinum toxin type B intravesical injections: report of 4 cases and review of the literature.Int Urol Nephrol2006; 38: 543–4.
20.
SmithCP, RadziszewskiP, BorkowskiA, SomogyiGT, BooneTB, ChancellorMB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis.Urology2004; 64: 871–5.
21.
ChuangYC, ChancellorMB. The application of botulinum toxin in the prostate.J Urol2006; 176: 2375–82.
22.
LaiHH, SmithCP. Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders.Curr Urol Rep2007; 8: 351–8.
23.
MariaG, BrisindaG, CivelloIM, SgangaG, AlbaneseA. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.Urology2003; 62: 259–64.
24.
ChuangYC, ChiangPH, HuangCC, YoshimuraN, ChancellorMB. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates.Urology2005; 66: 775–9.
25.
ChuangYC, ChiangPH, YoshimuraN, De MiguelF, ChancellorMB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hypertrophy.BJU Int2006; 98: 1033–7.
26.
KuoHC. Prostate botulinum A toxin injection: an alternative treatment for benign prostatic obstruction in poor surgical candidates.Urology2005; 65: 670–74.
27.
SilvaJ, SilvaC, SaraivaL, SilvaA, PintoR, CruzF. Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.Eur Urol2008; 53: 153–9.
28.
ChuangYC, YoshimuraN, WuM. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A.Eur Urol2007; 51: 1119–2.
29.
JarvisSK, AbbottJA, LenartMB, SteensmaA, VancaillieTG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles.Aust N Z J Obstet Gynaecol2004; 44: 46–50.
30.
AbbottJA, JarvisSK, LyonsSD, ThompsonA, VancailleTG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial.Obstet Gynecol2006; 108: 915–23.
31.
GhazizadehS, NikzadM. Botulinum toxin in the treatment of refractory vaginismus.Obstet Gynecol2004; 104: 922–5.
32.
BrownCS, GlazerHI, VogtV, MenkesD, BachmannG. Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data.J Reprod Med2006; 51: 635–41.
